Paul Anderson is the CEO and founding member of Orthocell Ltd which is a regenerative medicine company, listed on the Australian Securities Exchange (ASX: OCC) committed to improving the lives of patients suffering from serious musculoskeletal conditions by developing innovative products that restore patient mobility, function and performance. Orthocell’s two lead products are CelGro®, a superior collagen medical device that augments tissue repair and regeneration and Ortho-ATI®, the world leading cell therapy for treatment of chronic tendon injury.
Paul has 20 years experience in the health care sector and has worked in the commercial orthopaedic field for the past 16 years. He joined start up bio-therapy company Verigen in 1999 as Australian/South East Asian sales and marketing manager and led the introduction of an innovative cellular therapy intervention for the regeneration of articular cartilage of the joints. He was appointed the managing director’s role in 2002 and oversaw the companies GMP production facility and strategic development of the commercialisation of its technology. He also assisted in the international group’s eventual trade sale in 2005 to US Company Genzyme Inc.
In 2006 Paul co-founded Orthocell Pty Ltd to pursue his passion of developing and translating innovative biological therapies in the musculoskeletal area. Paul’s expertise lies in his intimate knowledge of the regenerative medicine fields, his understanding and management of GMP production facilities and the know how of taking cellular therapeutic and biological technologies from research to clinical applications.
Orthocell was publically listed in 2014 and has continued to validate and commercialise a range of differing products for bone, tendon, nerve and cartilage repair and regeneration.